Top 50 Life Science VC (Venture Capital) Funds in July 2025

Investor	Life Science investments
SOSV	51
ARCH Venture Partners	28
Sofinnova Partners	27
Alexandria Venture Investments	23
Northpond Ventures	20
Parkwalk Advisors	18
RA Capital Management	17
Novartis Venture Fund	17
OrbiMed	17
Google Ventures	16
Fifty Years	15
UK Innovation & Science Seed Fund	15
Oxford Science Enterprises	15
8VC	14
Atlas Venture	14
Versant Ventures	14
Third Rock Ventures	13
Civilization Ventures	13
DCVC	13
SR One	13
Bpifrance	13
Lux Capital	13
Alix Ventures	12
Prox Ventures	12
Hatteras Venture Partners	11
Kurma Partners	11
KdT Ventures	11
Horizons Ventures	11
M Ventures	11
Andreessen Horowitz	11
MPM Capital	11
Casdin Capital	10
Takeda Ventures	10
Novo Holdings	10
Roche Venture Fund	10
Dementia Discovery Fund	10
Sahsen Ventures	10
Omega Funds	10
Artis Ventures	10
F-Prime	9
Vivo Capital	9
Forbion Capital Partners	9
HTGF (High-Tech Gruenderfonds)	9
JDRF T1D Fund	9
New Enterprise Associates	9
5AM Ventures	9
Flagship Pioneering	9
Oxford Science Enterprises	9
Longwood Fund	9
Bioeconomy Capital	9

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Atlas Data Storage — Atlas Data Storage develops data storage systems utilizing synthetic DNA to encode digital information. The company offers end-to-end solutions that integrate semiconductor-based synthesis and enzyme engineering to store data in DNA strands. This approach aims to provide long-term, high-density storage options for various sectors. Atlas DataStorage's technology is designed to address the growing demand for scalable and energy-efficient data storage solutions.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

SafeHeal — SafeHeal is a clinical stage medical device manufacturer focusing on the development of anastomosis protection devices, including Colovac, for colorectal surgery.
Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Canada, France

Portfolio highlights

Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Northpond Ventures is a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and aﬃliated industries.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
illumion — Illumion develops high-throughput optical tools to accelerate battery material development
Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Post-IPO Equity
United States, United Kingdom, Canada

Portfolio highlights

Vor Biopharma — Shield the healthy cells, expose the cancer - Vor Bio (also known as Vor Biopharma) aims to cure blood cancers through cell and genome engineering.
Commons Clinic — Commons Clinic is a group of world class orthopedic surgeons in Los Angeles, CA. Our orthopedic specialists provide expert care from start to finish.
Spyglass Pharma — Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Alpheus Medical — Our Brain Cancer Clinical Trial is investigating Sonodynamic Therapy. A painless, non-invasive ultrasonic technology for the treatment of glioblastoma.
CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

PostHog — PostHog is the only all-in-one platform for product analytics, feature flags, session replays, experiments, and surveys that's built for developers.
OpenEvidence — OpenEvidence uses artificial intelligence to aggregate, synthesize, and visualize clinical evidence in understandable, clinically-useful formats that can be used to make more evidenced-based decisions and improve patient outcomes.
Glass Imaging — Traditional cameras rely on an imaging lens which typically consists of several lens elements and a light sensitive sensor. Cameras have been built like this since 1816. Glass has been historically used to make high quality optical elements. We are replacing these elements with deep neural networks that give extreme flexibility when designing ourcameras. It allows us to squeeze a huge sensor into an ultra thin module that fits perfectly into a mobile device without the need for protruding bumps. Our cameras bring SLR image quality into your pocket.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Cryogenx — Cryogenx body cooling technology is the ice bath in your backback. The defibrillator for heat.
digiLab — digiLab is an AI company building uncertainty-aware, explainable software for critical industries like fusion energy, defence, sustainability, and advanced infrastructure. Its flagship platform, The Uncertainty Engine, helps organisations explore, reason, and decide with AI they can trust. Combining frontier science with pragmatic delivery, digiLabsupports customers across government and industry, and leads cutting-edge challenge projects through its applied research unit, theLab.
Sention Technologies — Applying advanced diagnostic techniques and machine learning to unlock a cell's full potential at any stage of its life. Optimising performance, reducing cost, and improving safety for any cell

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Memebox — Memebox Corporation is a consumer company that provides customers with the Asian beauty products, culture, and trends. A global company focused on forecasting trends and creating private, in-house labels inspired by K-beauty (and made for the product obsessed).
Portal Biotech — Portal has created next generation solutions that address the significant opportunities in protein sequencing and metabolomics
Bedrock Robotics — Bedrock Robotics delivers enhanced autonomy to the built environment, allowing the construction sector to build at the rate that today's society requires.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Vima Therapeutics — There are over 1 million people with dystonia and related movement disorders in the US and over 100,000 people with isolated dystonia.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Antheia — Transforming pharmaceutical supply chains using synthetic biology, to end drug shortages and unlock new opportunities in development and discovery
SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Eytrix — Eytrix enables governments and enterprises to query their security camera systems with ease, using natural language to search past footage (“Find a man with a blue backpack”), set up intelligent alerts (“Alert me if someone climbs over the wall”), and extract meaningful data from video streams (“How many vehicles entered yesterday?”)—all through aseamless, AI-powered interface.
Halter — Halter creates GPS enabled, solar powered collars for cows. The collar hardware allows farmers to use simple tablet app software to remotely set geographic boundaries for cattle, virtual fences. Farmers use Halter's system to avoid physically herding cows, maximizing farmer time and productivity.
Impulse Space — Economical and nimble last-mile space payload delivery

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
ORIC Pharmaceuticals — ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
France, United States, Switzerland

Portfolio highlights

Animaj — Explore the future of storytelling where AI meets creativity at Animaj Lab. Join us on a journey to revolutionize kids' entertainment, crafting captivating content that keeps the digital-first generation engaged and inspired.
Veesion — Veesion: AI-driven smart video surveillance. Detect theft in real time. Protect your business now.
DejaBlue — The unified electrification offering for smarter, greener businesses.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Armada — The Armada Platform is a whole new way to succeed at the Edge with Starlink connectivity, mobile data centers & AI. Schedule a demo today.
Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
Hadrian — We are building the planet's most efficient factory to accelerate a democratic, abundant, spacefaring future.

Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....

Investment focus

Health Care, Biotechnology, Life Science
Series A, Seed, Pre-Seed
United States

Portfolio highlights

Elegen — Skip cloning with NGS-verified, cell-free DNA up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, shipped globally in 6 to 8 business days. .
Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Investment focus

Medical, Biotechnology, Health Care
Seed, Funding Round, Series A
China, United States, United Kingdom

Portfolio highlights

Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
Tuanxiang Pharmaceutical — Tuanxiang Pharmaceutical is an innovative drug research and development company that combines traditional new drug research and development with the use of the world's leading unique phase separation technology.
Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Canada

Portfolio highlights

410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
Atsena Therapeutics — Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Seed, Series B
France, Switzerland, Spain

Portfolio highlights

DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

Investing in the deep science and technology that can propel humanity towards a radically better future.

Investment focus

Biotechnology, Artificial Intelligence, Software
Series A, Series B, Seed
United States, United Kingdom, Canada

Portfolio highlights

Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Biolinq — Introducing a revolutionary platform for metabolic health.
ChEmpower — ChEmpower is an advanced materials company that develops chemically reactive, abrasive-free planarization pads to improve chip yields and sustainability in semiconductor manufacturing.
Corvic AI — Corvic AI is pioneering a new era of Data-Centric AI Cognitive Infrastructure by transforming raw enterprise data into AI-ready intelligence.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Brazil

Portfolio highlights

OpenRouter — OpenRouter is a platform that connects AI applications with large language models and cloud hosting providers, allowing users to optimize for costs, speed, and performance. The platform supports over 180 AI models, offers a unified API, and includes functionalities like private chat and exploratory data capabilities. OpenRouter sets the newbenchmark for large-scale AI inference with its global edge infrastructure, privacy-focused design, real-time accounting, and integrated billing.
Shield USDT — Shield is the first B2B cryptocurrency exchange designed for international businesses. Access a US-based virtual bank account to buy, sell, and transfer crypto.
Abridge — For patients, clinicians, and enterprise, our audio-based solutions capture the details and summarize medical conversations, anywhere care happens.

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Canada, United Kingdom

Portfolio highlights

āshibio — āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course.
Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, France, China

Portfolio highlights

Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Auron Therapeutics — A differentiated approach to cure cancer.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Investment focus

Biotechnology, Health Care, Non Profit
Funding Round, Series A, Seed
United States, China, Ghana

Portfolio highlights

Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Alleviant Medical — Interventional therapy for congestive heart failure
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.

Investment focus

Health Care, Biotechnology, Software
Series A, Series B, Seed
United States, India, Germany

Portfolio highlights

Network Bio — Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Dinari — Discover Equity Boundless - Simplify everything from equity management and options grant to payroll so that you no longer have to worry about compliance, taxes, or vesting schedules no matter where your employees are.
Dataplor — Leveraging machine learning, AI, and human capital, dataplor delivers verified international places data to the world's leading companies.
Canary Technologies — Use Canary to securely conduct contactless check-in and process credit card authorizations, contracts, and amenities online. Canary is the only PCI Level-1 Compliant solution for hotel authorizations. Schedule a demo today, and see how we can help your properties reduce chargebacks, save time, and improve the guest experience.

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series C, Post-IPO Equity
United States, China, United Kingdom

Portfolio highlights

35Pharma — 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Eeden — Eeden engages in the manufacture and supply of textiles.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
nuuEnergy — nuuEnergy is a tech-enabled solution aiming to revolutionize the heat pump installation industry. By leveraging technology and industry expertise, we streamline the purchasing and installation process. Our unique approach, refinanced through innovative strategies, promotes a self-reliant and carbon-neutral lifestyle for all our customers.
Steuerboard — Steuerboard serves as a collaborative platform facilitating digital interaction between tax advisors and clients. The mission of Steuerboard is to rethink the way accountants and clients work together.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, France, Italy

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Cour Pharmaceuticals Development — Reprogramming the immune system. Restoring lives.At COUR, we develop targeted therapies that incite calm within the immune system and help restore the healt ...

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Series C
United States, India, Canada

Portfolio highlights

NG.CASH — NG.CASH is a digital app designed to help Generation Z become financially independent. It allows users to manage their own money with solutions such as PIX (Brazil’s “instant-payment” method), prepaid credit card, allowance management and a virtual card, in addition to features that let users customise the app’s design and a marketplace withdiscounts on Gen Z’s most desired brands. Structured as a financial hub, NG.CASH aims to accompany its clients throughout their lives and increase financial literacy in the region.
Wispr Flow — Wispr AI is a developer of the next-generation of neural interfaces to provide seamless interface with immersive technology. The company is working with the leading neuroscientist, hardware engineers, machine learning researchers, and product engineers to bring frontier technology to the mass consumer market.
Spyglass Pharma — Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Surrozen — Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.

We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Canada, United Kingdom

Portfolio highlights

Etiome — Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.
Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Series B, Series C
United States, United Kingdom, Italy

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Bioeconomy Capital invests in early-stage companies with the goal of accelerating the biotechnology revolution. Based on its startup operational expertise, product development experience, and globally recognized strategic analysis, it has developed a blueprint for building and deploying technological capabilities that will become a criticalinfrastructure of the 21st-century economy.The company's proprietary blueprint is the distillation of the fund managers' five decades of combined experience in synthetic biology and other engineering fields and cannot be readily duplicated. Prior investments include Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences.

Investment focus

Biotechnology, Life Science, Pharmaceutical
Series A, Series B, Seed
United States, United Kingdom

Portfolio highlights

MicroByre — MicroByre is a platform for bacterial domestication. Their automated characterization pipeline gathers the oft-overlooked data that highlights unleveraged bacteria that meet functional industrial criteria. That is, they rapidly find the bacteria with naturally unfussy eating habits and evolution-honed metabolisms that have the potential to convertunrefined biomasses into commodity chemicals at vastly improved efficiencies compared to extant fermentation processes. They select from these functionally de-risked bacteria those which can be directly genetically modified to improve their cost profiles — even if they have never been engineered before. The data from our unique characterization pipeline informs the minimally precise genetic modifications necessary to increase pliability and yield, eliminate nutritional additives, maximize feedstock utilization, and improve contamination tolerance & phage resistance. MicroByre gives biomass conversion a truly competitive edge against petrochemical synthesis.MicroByre’s platform bridges the gap between the promising and the profitable in synthetic biology and bioengineering. A unique combination of resources and skills makes MicroByre a valuable potential partner for companies of all sizes and industries. They collaborate to define project scope to match a mutually agreeable business model, which could be a fee for service, license agreement, or joint development agreement.
Tandem PV — Discover the future of sustainable energy with Tandem PV, a leader in perovskite solar technology and innovative solar energy solutions.
Parse Biosciences — Parse Biosciences is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. Learn more about how you can use the most scalable single cell platform on the market without the need for custom instrumentation.